Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity
Catherine Matte-Martone, … , John T. Harty, Warren D. Shlomchik
Catherine Matte-Martone, … , John T. Harty, Warren D. Shlomchik
Published June 12, 2017
Citation Information: J Clin Invest. 2017;127(7):2765-2776. https://doi.org/10.1172/JCI85736.
View: Text | PDF
Research Article Immunology Article has an altmetric score of 2

Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity

  • Text
  • PDF
Abstract

The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (alloSCT) is potent against chronic phase chronic myelogenous leukemia (CP-CML), but blast crisis CML (BC-CML) and acute myeloid leukemias (AML) are GVL resistant. To understand GVL resistance, we studied GVL against mouse models of CP-CML, BC-CML, and AML generated by the transduction of mouse BM with fusion cDNAs derived from human leukemias. Prior work has shown that CD4+ T cell–mediated GVL against CP-CML and BC-CML required intact leukemia MHCII; however, stem cells from both leukemias were MHCII negative. Here, we show that CP-CML, BC-CML, and AML stem cells upregulate MHCII in alloSCT recipients. Using gene-deficient leukemias, we determined that BC-CML and AML MHC upregulation required IFN-γ stimulation, whereas CP-CML MHC upregulation was independent of both the IFN-γ receptor (IFN-γR) and the IFN-α/β receptor IFNAR1. Importantly, IFN-γR–deficient BC-CML and AML were completely resistant to CD4- and CD8-mediated GVL, whereas IFN-γR/IFNAR1 double-deficient CP-CML was fully GVL sensitive. Mouse AML and BC-CML stem cells were MHCI+ without IFN-γ stimulation, suggesting that IFN-γ sensitizes these leukemias to T cell killing by mechanisms other than MHC upregulation. Our studies identify the requirement of IFN-γ stimulation as a mechanism for BC-CML and AML GVL resistance, whereas independence from IFN-γ renders CP-CML more GVL sensitive, even with a lower-level alloimmune response.

Authors

Catherine Matte-Martone, Jinling Liu, Meng Zhou, Maria Chikina, Douglas R. Green, John T. Harty, Warren D. Shlomchik

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 Total
Citations: 2 4 3 3 3 5 2 22
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (22)

Title and authors Publication Year
IFN-gamma and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation 
Sawa Ito, Emily M Geramita, Kedwin Ventura, Biswas Neupane, Shruti S Bhise, Erika M. Moore, Scott N Furlan, Warren Shlomchik
JCI Insight 2025
Integrative analysis of epigenetic subtypes in acute myeloid Leukemia: A multi-center study combining machine learning for prognostic and therapeutic insights
Li J, Wang S
PLOS One 2025
The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Maurer K, Antin JH
Frontiers in immunology 2024
Maintenance strategies for relapse prevention and treatment
Geramita E, Hou JZ, Shlomchik WD, Ito S
Hematology: the American Society of Hematology Education Program 2024
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D\u2019Alessandro A, Sherbenou DW, Pollyea DA, Smith C, Jordan CT
Haematologica 2024
Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow
Zhao K, Zhu J, Rosenberger S, Zhou M, Shlomchik WD
Blood Advances 2024
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A, D\u2019Aveni M, Aarnink A, Rubio MT, Feugier P, Ferraro F, Carraway HE, Sobecks R, Hamilton BK, Majhail NS, Visconte V, Maciejewski JP
Research square 2023
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.
Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A, D'Aveni M, Aarnink A, Rubio MT, Feugier P, Ferraro F, Carraway HE, Sobecks R, Hamilton BK, Majhail NS, Visconte V, Maciejewski JP
Nature Communications 2023
The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation
Maurer K, Soiffer RJ
Expert Review of Hematology 2023
From drug repositioning to target repositioning: prediction of therapeutic targets using genetically perturbed transcriptomic signatures
Namba S, Iwata M, Yamanishi Y
Bioinformatics 2022
Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse.
Gambacorta V, Beretta S, Ciccimarra M, Zito L, Giannetti K, Andrisani A, Gnani D, Zanotti L, Oliveira G, Carrabba MG, Cittaro D, Merelli I, Ciceri F, Di Micco R, Vago L
Cancer Discovery 2022
Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells
Rimando JC, Chendamarai E, Rettig MP, Jayasinghe R, Christopher MJ, Ritchey JK, Christ S, Kim MY, Bonvini E, DiPersio JF
Blood 2022
USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis
M Li, Y Xu, J Liang, H Lin, X Qi, F Li, P Han, Y Gao, X Yang
Molecular Therapy 2021
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation
JC Rimando, MJ Christopher, MP Rettig, JF DiPersio
Journal of Clinical Oncology 2021
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.
Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, Wang M, Chen H, Chen YH, Wang FR, Wei-Han, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ
Cellular & molecular immunology 2021
Granzyme A-producing T helper cells are critical for acute graft-versus-host disease.
Sungtae Park, Brad Griesenauer, Hua Jiang, Djamilatou Adom, Pegah Mehrpouya-Bahrami, Srishti Chakravorty, Majid Kazemian, Tanbeena Imam, Rajneesh Srivastava, Tristan A. Hayes, Julian Pardo, Sarath Chandra Janga, Sophie Paczesny, Mark H. Kaplan, Matthew R. Olson
JCI Insight 2020
T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect
M Zhou, F Sacirbegovic, K Zhao, S Rosenberger, WD Shlomchik
Nature Communications 2020
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
BR Blazar, GR Hill, WJ Murphy
Nature Reviews Clinical Oncology 2020
H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect
EY Choi, K Choi, G Nam, W Kim, M Chung
Frontiers in immunology 2020
ATG5-dependent autophagy uncouples T cell proliferative and effector functions and separates graft-versus-host disease from graft- versus-leukemia
Oravecz-Wilson K, Rossi C, Zajac C, Sun Y, Li L, Decoville T, Fujiwara H, Kim S, Peltier D, Reddy P
Cancer research 2020
The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease
M Koyama, GR Hill
Blood 2019
C/EBPβ is a critical mediator of IFN-α–induced exhaustion of chronic myeloid leukemia stem cells
A Yokota, H Hirai, R Sato, H Adachi, F Sato, Y Hayashi, A Sato, N Kamio, Y Miura, M Nakano, , S Kimura, K Tashiro, T Maekawa
Blood Advances 2019

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 4 X users
26 readers on Mendeley
See more details